Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib.

Manur R, Sung PJ, Loren AW, Ritchie EK, Frank D, Bagg A, Geyer JT, Bogusz AM.

Leuk Lymphoma. 2019 Sep 16:1-5. doi: 10.1080/10428194.2019.1660975. [Epub ahead of print] No abstract available.

PMID:
31524018
2.

Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea.

Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R.

Blood. 2019 Sep 12. pii: blood.2019000428. doi: 10.1182/blood.2019000428. [Epub ahead of print]

PMID:
31515250
3.

Drug development challenges in polycythemia vera.

Ritchie EK.

Blood. 2019 Aug 8;134(6):495-496. doi: 10.1182/blood.2019001875. No abstract available.

PMID:
31395580
4.

Interactions among Ryanodine Receptor isotypes contribute to muscle fiber type development and function.

Chagovetz AA, Klatt Shaw D, Ritchie E, Hoshijima K, Grunwald DJ.

Dis Model Mech. 2019 Aug 5. pii: dmm.038844. doi: 10.1242/dmm.038844. [Epub ahead of print]

5.

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R.

Leukemia. 2019 Jul 30. doi: 10.1038/s41375-019-0524-7. [Epub ahead of print] No abstract available.

PMID:
31363161
6.

Lethal and Sublethal Toxicity of Thiamethoxam and Clothianidin Commercial Formulations to Soil Invertebrates in a Natural Soil.

Ritchie EE, Maisonneuve F, Scroggins RP, Princz JI.

Environ Toxicol Chem. 2019 Jun 18. doi: 10.1002/etc.4521. [Epub ahead of print]

PMID:
31211447
7.

Splenogonadal fusion: A case of two lesions.

Mann JA, Ritchie E.

Urol Case Rep. 2019 Mar 20;24:100878. doi: 10.1016/j.eucr.2019.100878. eCollection 2019 May.

8.

Opportunities to improve influenza vaccination rates in general medical inpatients.

Zaman FY, Nagalingam V, Wong C, Khu YL, Teng HWG, Janardan J, Ritchie E, Cheng AC, Aung AK.

Intern Med J. 2019 May;49(5):662-665. doi: 10.1111/imj.14275.

PMID:
31083800
9.

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR.

Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.

PMID:
31060979
10.

Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Jun;81:105. doi: 10.1016/j.leukres.2019.04.006. Epub 2019 Apr 24. No abstract available.

PMID:
31029462
11.

Mainstreaming human and large carnivore coexistence through institutional collaboration.

Hartel T, Scheele BC, Vanak AT, Rozylowicz L, Linnell JDC, Ritchie EG.

Conserv Biol. 2019 Apr 18. doi: 10.1111/cobi.13334. [Epub ahead of print]

PMID:
30997704
12.

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Apr;79:38-44. doi: 10.1016/j.leukres.2019.02.012. Epub 2019 Feb 28. Erratum in: Leuk Res. 2019 Jun;81:105.

PMID:
30849661
13.

Improving the assessment of food system sustainability.

Hadjikakou M, Ritchie EG, Watermeyer KE, Bryan BA.

Lancet Planet Health. 2019 Feb;3(2):e62-e63. doi: 10.1016/S2542-5196(18)30244-4. No abstract available.

14.

Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.

Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL.

Leuk Lymphoma. 2019 Jun;60(6):1476-1484. doi: 10.1080/10428194.2018.1538510. Epub 2019 Jan 22.

PMID:
30668234
15.

Animal movements in fire-prone landscapes.

Nimmo DG, Avitabile S, Banks SC, Bliege Bird R, Callister K, Clarke MF, Dickman CR, Doherty TS, Driscoll DA, Greenville AC, Haslem A, Kelly LT, Kenny SA, Lahoz-Monfort JJ, Lee C, Leonard S, Moore H, Newsome TM, Parr CL, Ritchie EG, Schneider K, Turner JM, Watson S, Westbrooke M, Wouters M, White M, Bennett AF.

Biol Rev Camb Philos Soc. 2019 Jun;94(3):981-998. doi: 10.1111/brv.12486. Epub 2018 Dec 18.

PMID:
30565370
16.

Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications.

Ritchie EK.

Leuk Lymphoma. 2019 May;60(5):1116-1125. doi: 10.1080/10428194.2018.1535114. Epub 2018 Nov 27.

PMID:
30481083
17.

Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.

Gergis U, Frenet EM, Shore T, Mayer S, Phillips A, Hsu JM, Roboz G, Ritchie E, Scandura J, Lee S, Desai P, Samuel M, Ball J, Blanco A, Romeo C, Albano MS, Dobrila L, Scaradavou A, van Besien K.

Biol Blood Marrow Transplant. 2019 Mar;25(3):466-473. doi: 10.1016/j.bbmt.2018.11.002. Epub 2018 Nov 9.

PMID:
30414955
18.

Species definitions shape policy.

Ritchie EG, Smith BP, van Eeden LM, Nimmo DG.

Science. 2018 Sep 28;361(6409):1324. doi: 10.1126/science.aav3437. No abstract available.

PMID:
30262492
19.

Expanding the Role of Targets in Conservation Policy.

Doherty TS, Bland LM, Bryan BA, Neale T, Nicholson E, Ritchie EG, Driscoll DA.

Trends Ecol Evol. 2018 Nov;33(11):809-812. doi: 10.1016/j.tree.2018.08.014. Epub 2018 Sep 19.

PMID:
30243834
20.

Interplay of Surface Recombination and Diode Geometry for the Performance of Axial p-i-n Nanowire Solar Cells.

Hill DJ, Teitsworth TS, Ritchie ET, Atkin JM, Cahoon JF.

ACS Nano. 2018 Oct 23;12(10):10554-10563. doi: 10.1021/acsnano.8b06577. Epub 2018 Sep 25.

PMID:
30235417
21.

Carnivore conservation needs evidence-based livestock protection.

van Eeden LM, Eklund A, Miller JRB, López-Bao JV, Chapron G, Cejtin MR, Crowther MS, Dickman CR, Frank J, Krofel M, Macdonald DW, McManus J, Meyer TK, Middleton AD, Newsome TM, Ripple WJ, Ritchie EG, Schmitz OJ, Stoner KJ, Tourani M, Treves A.

PLoS Biol. 2018 Sep 18;16(9):e2005577. doi: 10.1371/journal.pbio.2005577. eCollection 2018 Sep.

22.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

23.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC.

J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.

24.

Somatic mutations precede acute myeloid leukemia years before diagnosis.

Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV, Roboz GJ, Hassane DC.

Nat Med. 2018 Jul;24(7):1015-1023. doi: 10.1038/s41591-018-0081-z. Epub 2018 Jul 9.

PMID:
29988143
25.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2. No abstract available.

PMID:
29963936
26.

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.

Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, Davis FN, Ritchie EC, Lubenow TR, Hooten WM.

Reg Anesth Pain Med. 2018 Jul;43(5):521-546. doi: 10.1097/AAP.0000000000000808. Review.

27.

Crowdfunding biodiversity conservation.

Gallo-Cajiao E, Archibald C, Friedman R, Steven R, Fuller RA, Game ET, Morrison TH, Ritchie EG.

Conserv Biol. 2018 Dec;32(6):1426-1435. doi: 10.1111/cobi.13144. Epub 2018 Sep 6.

PMID:
29802734
28.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

29.

Testing the assumptions of the pyrodiversity begets biodiversity hypothesis for termites in semi-arid Australia.

Davis H, Ritchie EG, Avitabile S, Doherty T, Nimmo DG.

R Soc Open Sci. 2018 Apr 25;5(4):172055. doi: 10.1098/rsos.172055. eCollection 2018 Apr.

30.

Intracellular Calcium Mobilization Is Required for Sonic Hedgehog Signaling.

Klatt Shaw D, Gunther D, Jurynec MJ, Chagovetz AA, Ritchie E, Grunwald DJ.

Dev Cell. 2018 May 21;45(4):512-525.e5. doi: 10.1016/j.devcel.2018.04.013. Epub 2018 May 10.

31.

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.

Roboz GJ, Ritchie EK, Dault Y, Lam L, Marshall DC, Cruz NM, Hsu HC, Hassane DC, Christos PJ, Ippoliti C, Scandura JM, Guzman ML.

Haematologica. 2018 Aug;103(8):1308-1316. doi: 10.3324/haematol.2017.183418. Epub 2018 May 3.

32.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

33.

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9.

34.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.

BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.

35.

A biodiversity-crisis hierarchy to evaluate and refine conservation indicators.

Driscoll DA, Bland LM, Bryan BA, Newsome TM, Nicholson E, Ritchie EG, Doherty TS.

Nat Ecol Evol. 2018 May;2(5):775-781. doi: 10.1038/s41559-018-0504-8. Epub 2018 Mar 26. Review.

PMID:
29581587
36.

Analysis of serum cortisol to predict recovery in paediatric sport-related concussion.

Ritchie EV, Emery C, Debert CT.

Brain Inj. 2018;32(4):523-528. doi: 10.1080/02699052.2018.1429662. Epub 2018 Feb 5.

PMID:
29400570
37.

Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?

Atallah E, Ritchie E.

Expert Opin Pharmacother. 2018 Feb;19(2):79-81. doi: 10.1080/14656566.2017.1421633. Epub 2018 Jan 7. No abstract available.

PMID:
29308683
38.

Effect of Antibiotic Prophylaxis on Surgical Site Infections Following Removal of Orthopedic Implants Used for Treatment of Foot, Ankle, and Lower Leg Fractures: A Randomized Clinical Trial.

Backes M, Dingemans SA, Dijkgraaf MGW, van den Berg HR, van Dijkman B, Hoogendoorn JM, Joosse P, Ritchie ED, Roerdink WH, Schots JPM, Sosef NL, Spijkerman IJB, Twigt BA, van der Veen AH, van Veen RN, Vermeulen J, Vos DI, Winkelhagen J, Goslings JC, Schepers T; WIFI Collaboration Group.

JAMA. 2017 Dec 26;318(24):2438-2445. doi: 10.1001/jama.2017.19343. Erratum in: JAMA. 2018 Mar 13;319(10 ):1051.

39.

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ.

Cancer. 2018 Jan 15;124(2):325-334. doi: 10.1002/cncr.31138. Epub 2017 Dec 6.

40.
41.

Mapping Free-Carriers in Multijunction Silicon Nanowires Using Infrared Near-Field Optical Microscopy.

Ritchie ET, Hill DJ, Mastin TM, Deguzman PC, Cahoon JF, Atkin JM.

Nano Lett. 2017 Nov 8;17(11):6591-6597. doi: 10.1021/acs.nanolett.7b02340. Epub 2017 Oct 30.

PMID:
29032679
42.

Discharge communication practices and healthcare provider and patient preferences, satisfaction and comprehension: A systematic review.

Newnham H, Barker A, Ritchie E, Hitchcock K, Gibbs H, Holton S.

Int J Qual Health Care. 2017 Oct 1;29(6):752-768. doi: 10.1093/intqhc/mzx121. Review.

PMID:
29025093
43.

United we stand, divided we conquer: pilot study of multidisciplinary General Medicine Heart Failure Care Program.

Wahbi-Izzettin O, Hopper I, Ritchie E, Nagalingam V, Aung AK.

Intern Med J. 2018 Feb;48(2):178-183. doi: 10.1111/imj.13647.

PMID:
29024333
44.

Human-modified habitats facilitate forest-dwelling populations of an invasive predator, Vulpes vulpes.

Hradsky BA, Robley A, Alexander R, Ritchie EG, York A, Di Stefano J.

Sci Rep. 2017 Sep 25;7(1):12291. doi: 10.1038/s41598-017-12464-7.

45.

Improving Veteran Engagement With Mental Health Care.

Ritchie EC.

Fed Pract. 2017 Aug;34(8):55-56. No abstract available.

46.

Defending the scientific integrity of conservation-policy processes.

Carroll C, Hartl B, Goldman GT, Rohlf DJ, Treves A, Kerr JT, Ritchie EG, Kingsford RT, Gibbs KE, Maron M, Watson JEM.

Conserv Biol. 2017 Oct;31(5):967-975. doi: 10.1111/cobi.12958. Epub 2017 Jul 25.

PMID:
28741747
47.

CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, Hassane DC, Guzman ML.

Leuk Lymphoma. 2018 Apr;59(4):821-828. doi: 10.1080/10428194.2017.1352089. Epub 2017 Jul 18.

48.

The ecotoxicity of zinc and zinc-containing substances in soil with consideration of metal-moiety approaches and organometal complexes.

Ritchie E, Boyd P, Lawson-Halasz A, Hawari J, Saucier S, Scroggins R, Princz J.

Environ Toxicol Chem. 2017 Dec;36(12):3324-3332. doi: 10.1002/etc.3910. Epub 2017 Aug 23.

PMID:
28708298
49.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

50.

Managing conflict between large carnivores and livestock.

van Eeden LM, Crowther MS, Dickman CR, Macdonald DW, Ripple WJ, Ritchie EG, Newsome TM.

Conserv Biol. 2018 Feb;32(1):26-34. doi: 10.1111/cobi.12959. Epub 2017 Jul 5. Review.

PMID:
28556528

Supplemental Content

Loading ...
Support Center